CIBC Asset Management’s Integra LifeSciences IART Stock Holding History

CIBC Asset Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,558	Closed	-$229K	–	1369
2022 Q1	$229K	Hold	3,558	–	–	﹤0.01%	1260
2021 Q4	$238K	Buy	3,558 +160	+5%	+$10.8K	﹤0.01%	1252
2021 Q3	$233K	Buy	3,398 +303	+10%	+$21.4K	﹤0.01%	1225
2021 Q2	$211K	Hold	3,095	–	–	﹤0.01%	1254
2021 Q1	$214K	Sell	3,095 -226	-7%	-$15.3K	﹤0.01%	1202
2020 Q4	$216K	Buy	+3,321	New	+$179K	﹤0.01%	1097
2018 Q2	–	Sell	-5,116	Closed	-$283K	–	1139
2018 Q1	$283K	Hold	5,116	–	–	﹤0.01%	827
2017 Q4	$245K	Buy	5,116 +240	+5%	+$11.7K	﹤0.01%	900
2017 Q3	$246K	Buy	4,876 +280	+6%	+$14.4K	﹤0.01%	874
2017 Q2	$251K	Buy	+4,596	New	+$219K	﹤0.01%	835

Other funds holding IART

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

CIBC Asset Management's IART Position: Q2 2022 in Review

CIBC Asset Management sold out of Integra LifeSciences (IART) in Q2 2022, closing a stake of 3,558 shares — an estimated $229K sold.

CIBC Asset Management first reported a position in IART in Q2 2017 and held it in 10 quarters. The position peaked at $283K in Q1 2018. 284 funds tracked by Wall St. Rank hold IART as of Q2 2022.

CIBC Asset Management reported no remaining Integra LifeSciences position as of Q2 2022 after selling out during the quarter.
CIBC Asset Management sold 3,558 Integra LifeSciences shares in Q2 2022, an estimated $229K.
CIBC Asset Management first reported a position in Integra LifeSciences in Q2 2017 and held it in 10 quarters.
CIBC Asset Management's Integra LifeSciences position peaked at $283K in Q1 2018.
284 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2022.

Based on CIBC Asset Management's 13F filing for Q2 2022, filed 9 Aug 2022.